Comparative effectiveness and safety of a catheterization laboratory-only Eptifibatide dosing strategy in patients undergoing percutaneous coronary intervention

Circulation: Cardiovascular Interventions

Volumn 8, Issue 2, 2015, Pages

  Gurm, Hitinder S ^a   Hosman, Carrie ^b   Bates, Eric R ^a   Share, David ^c   Hansen, Ben B ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

^c Blue Cross Blue Shield of Michigan Cardiovascular Consortium   (United States)

Author keywords

Eptifibatide; Percutaneous coronary intervention

Indexed keywords

BETA1 INTEGRIN; EPTIFIBATIDE; GLYCOPROTEIN IIB; ANTITHROMBOCYTIC AGENT; PEPTIDE;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR MORTALITY; CLINICAL PRACTICE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; OFF LABEL DRUG USE; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACEUTICAL CARE; PRIORITY JOURNAL; PROPENSITY SCORE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; ADVERSE EFFECTS; AGED; CHEMICALLY INDUCED; COMPARATIVE STUDY; CORONARY DISEASE; DRUG ADMINISTRATION; HEART CATHETERIZATION; HEMORRHAGE; INFUSION; INJECTION; LABORATORY; MALE; MIDDLE AGED; MORTALITY; MYOCARDIAL INFARCTION; REGISTER; RISK; RISK FACTOR; TREATMENT OUTCOME; UNITED STATES;

AGED; BLOOD TRANSFUSION; CARDIAC CATHETERIZATION; COMPARATIVE EFFECTIVENESS RESEARCH; CORONARY DISEASE; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMORRHAGE; HOSPITAL MORTALITY; HUMANS; INFUSIONS, PARENTERAL; INJECTIONS; LABORATORIES; MALE; MICHIGAN; MIDDLE AGED; MYOCARDIAL INFARCTION; ODDS RATIO; OFF-LABEL USE; PEPTIDES; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84925844170     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.114.001880     Document Type: Article

References (27)

1. Topol EJ, Byzova TV, Plow EF. Platelet GPIIb-IIIa blockers. Lancet. 1999;353:227-231. doi: 10.1016/S0140-6736 (98) 11086-3.
2. Roffi M, Chew DP, Mukherjee D, Bhatt DL, White JA, Moliterno DJ, Heeschen C, Hamm CW, Robbins MA, Kleiman NS, Théroux P, White HD, Topol EJ. Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J. 2002;23:1441-1448.
3. Kong DF, Hasselblad V, Harrington RA, White HD, Tcheng JE, Kandzari DE, Topol EJ, Califf RM. Meta-analysis of survival with platelet glycoprotein IIb/IIIa antagonists for percutaneous coronary interventions. Am J Cardiol. 2003;92:651-655.
4. ESPRIT Investigators. Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebocontrolled trial. Lancet. 2000;356:2037.
5. Tcheng JE, Talley JD, O'Shea JC, Gilchrist IC, Kleiman NS, Grines CL, Davidson CJ, Lincoff AM, Califf RM, Jennings LK, Kitt MM, Lorenz TJ. Clinical pharmacology of higher dose eptifibatide in percutaneous coronary intervention (the PRIDE study). Am J Cardiol. 2001;88:1097-1102.
6. Scarborough RM. Development of eptifibatide. Am Heart J. 1999;138(6 pt 1):1093-1104.
7. Phillips DR, Scarborough RM. Clinical pharmacology of eptifibatide. Am J Cardiol. 1997;80(4A):11B-20B.
8. Fung AY, Saw J, Starovoytov A, Densem C, Jokhi P, Walsh SJ, Fox RS, Humphries KH, Aymong E, Ricci DR, Webb JG, Hamburger JN, Carere RG, Buller CE. Abbreviated infusion of eptifibatide after successful coronary intervention The BRIEF-PCI (Brief Infusion of Eptifibatide Following Percutaneous Coronary Intervention) randomized trial. J Am Coll Cardiol. 2009;53:837-845. doi: 10.1016/j.jacc.2008.09.060.
9. Marmur JD, Poludasu S, Agarwal A, Vladutiu P, Feit A, Lapin R, Cavusoglu E. Bolus-only platelet glycoprotein IIb-IIIa inhibition during percutaneous coronary intervention. J Invasive Cardiol. 2006;18:521-526.
10. Fischell TA, Attia T, Rane S, Salman W. High-dose, single-bolus eptifibatide: a safe and cost-effective alternative to conventional glycoprotein IIb/IIIa inhibitor use for elective coronary interventions. J Invasive Cardiol. 2006;18:487-491.
11. Gurm HS, Smith DE, Collins JS, Share D, Riba A, Carter AJ, LaLonde T, Kline-Rogers E, O'Donnell M, Changezi H, Zughaib M, Safian R, Moscucci M; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). The relative safety and efficacy of abciximab and eptifibatide in patients undergoing primary percutaneous coronary intervention: insights from a large regional registry of contemporary percutaneous coronary intervention. J Am Coll Cardiol. 2008;51:529-535. doi: 10.1016/j.jacc.2007.09.053.
12. Share DA, Campbell DA, Birkmeyer N, Prager RL, Gurm HS, Moscucci M, Udow-Phillips M, Birkmeyer JD. How a regional collaborative of hospitals and physicians in Michigan cut costs and improved the quality of care. Health Aff (Millwood). 2011;30:636-645. doi: 10.1377/hlthaff.2010.0526.
13. Kline-Rogers E, Share D, Bondie D, Rogers B, Karavite D, Kanten S, Wren P, Bodurka C, Fisk C, McGinnity J, Wright S, Fox S, Eagle KA, Moscucci M; Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2). Development of a multicenter interventional cardiology database: the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) experience. J Interv Cardiol. 2002;15:387-392.
14. Moscucci M, Rogers EK, Montoye C, Smith DE, Share D, O'Donnell M, Maxwell-Eward A, Meengs WL, De Franco AC, Patel K, McNamara R, McGinnity JG, Jani SM, Khanal S, Eagle KA. Association of a continuous quality improvement initiative with practice and outcome variations of contemporary percutaneous coronary interventions. Circulation. 2006;113:814-822. doi: 10.1161/CIRCULATIONAHA.105.541995.
15. Hansen BB, Klopfer S. Optimal full matching and related designs via network flows. J Comput Graph Stat. 2006;15:609-627.
16. Hansen BB. Full matching in an observational study of coaching for the SAT. J Am Stat Assoc. 2004;99:609-618.
17. Rosenbaum PR. Design of Observational Studies. New York: Springer; 2010.
18. Hansen BB, Bowers J. Covariate balance in simple, stratified and clustered comparative studies. Statist Sci. 2008;23:219-236.
19. Morgan SL, Harding DJ. Matching estimators of causal effects. Sociol Methods Res. 2006;35:3-60.
20. Agresti A. An Introduction to Categorical Data Analysis. Hoboken, NJ: John Wiley and Sons; 2002:250.
21. Brener SJ, Ellis SG, Schneider J, Apperson-Hansen C, Topol EJ. Abciximabfacilitated percutaneous coronary intervention and long-term survival-a prospective single-center registry. Eur Heart J. 2003;24:630-638.
22. EPIC. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med. 1994;330:956-961.
23. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
24. EPISTENT Investigators. Randomised placebo-controlled and balloonangioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352:87-92.
25. Kini AS, Chen VH, Krishnan P, Lee P, Kim MC, Mares A, Suleman J, Moreno PR, Sharma SK. Bolus-only versus bolus + infusion of glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. Am Heart J. 2008;156:513-519. doi: 10.1016/j.ahj.2008.04.019.
26. Valgimigli M, Tebaldi M, Campo G, Gambetti S, Bristot L, Monti M, Parrinello G, Ferrari R; FABOLUS PRO Investigators. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv. 2012;5:268-277. doi: 10.1016/j.jcin. 2012.01.006.
27. Kirtane AJ, Piazza G, Murphy SA, Budiu D, Morrow DA, Cohen DJ, Peterson E, Lakkis N, Herrmann HC, Palabrica TM, Gibson CM; TIMI Study Group. Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol. 2006;47:2374-2379. doi: 10.1016/j.jacc.2005.09.080.